ADMA Biologics (NASDAQ:ADMA) Sets New 1-Year High at $13.02

ADMA Biologics, Inc. (NASDAQ:ADMA)’s stock price hit a new 52-week high on Monday . The company traded as high as $13.02 and last traded at $13.02, with a volume of 22072 shares. The stock had previously closed at $12.78.

Wall Street Analyst Weigh In

ADMA has been the subject of several research reports. Cantor Fitzgerald increased their price target on shares of ADMA Biologics from $10.00 to $15.00 and gave the company an “overweight” rating in a research report on Tuesday, July 9th. HC Wainwright increased their target price on shares of ADMA Biologics from $7.50 to $10.00 and gave the company a “buy” rating in a research report on Friday, May 10th. Raymond James raised their price target on shares of ADMA Biologics from $8.00 to $10.00 and gave the stock a “strong-buy” rating in a research note on Friday, May 10th. Finally, Mizuho upped their price objective on ADMA Biologics from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Thursday, June 20th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $12.25.

ADMA Biologics Price Performance

The company has a debt-to-equity ratio of 0.91, a current ratio of 5.21 and a quick ratio of 1.86. The firm’s 50 day moving average price is $10.15 and its two-hundred day moving average price is $7.25.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Thursday, May 9th. The biotechnology company reported $0.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.05 by $0.03. The business had revenue of $81.90 million during the quarter, compared to analyst estimates of $77.28 million. ADMA Biologics had a negative net margin of 1.29% and a positive return on equity of 17.24%. ADMA Biologics’s revenue was up 43.9% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.03) EPS. On average, equities research analysts anticipate that ADMA Biologics, Inc. will post 0.35 EPS for the current fiscal year.

Insider Buying and Selling

In other ADMA Biologics news, CEO Adam S. Grossman sold 100,000 shares of ADMA Biologics stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $10.72, for a total transaction of $1,072,000.00. Following the completion of the transaction, the chief executive officer now owns 2,081,475 shares of the company’s stock, valued at approximately $22,313,412. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 3.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On ADMA Biologics

Institutional investors and hedge funds have recently modified their holdings of the company. Alberta Investment Management Corp lifted its holdings in shares of ADMA Biologics by 32.4% in the fourth quarter. Alberta Investment Management Corp now owns 460,774 shares of the biotechnology company’s stock worth $2,083,000 after buying an additional 112,831 shares in the last quarter. BNP Paribas Financial Markets grew its position in ADMA Biologics by 152.2% during the first quarter. BNP Paribas Financial Markets now owns 732,920 shares of the biotechnology company’s stock valued at $4,837,000 after acquiring an additional 442,315 shares during the last quarter. American Century Companies Inc. grew its position in ADMA Biologics by 20.8% during the third quarter. American Century Companies Inc. now owns 4,892,123 shares of the biotechnology company’s stock valued at $17,514,000 after acquiring an additional 840,761 shares during the last quarter. SG Americas Securities LLC grew its position in ADMA Biologics by 417.3% during the fourth quarter. SG Americas Securities LLC now owns 93,236 shares of the biotechnology company’s stock valued at $421,000 after acquiring an additional 75,213 shares during the last quarter. Finally, Victory Capital Management Inc. grew its position in ADMA Biologics by 23.0% during the fourth quarter. Victory Capital Management Inc. now owns 29,192 shares of the biotechnology company’s stock valued at $132,000 after acquiring an additional 5,465 shares during the last quarter. 75.68% of the stock is owned by hedge funds and other institutional investors.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.